Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Bisphosphonates and Breast Cancer Survival.
Strobl S, Korkmaz B, Devyatko Y, Schuetz M, Exner R, Dubsky PC, Jakesz R, Gnant M. Strobl S, et al. Among authors: devyatko y. Annu Rev Med. 2016;67:1-10. doi: 10.1146/annurev-med-053014-103600. Epub 2015 Aug 28. Annu Rev Med. 2016. PMID: 26332000 Review.
Optimal duration of adjuvant endocrine therapy: how to apply the newest data.
Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, Fitzal F, Gnant M. Wimmer K, et al. Among authors: devyatko y. Ther Adv Med Oncol. 2017 Nov;9(11):679-692. doi: 10.1177/1758834017732966. Epub 2017 Oct 27. Ther Adv Med Oncol. 2017. PMID: 29344105 Free PMC article. Review.
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.
Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M. Strobl S, et al. Among authors: devyatko y. Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Curr Treat Options Oncol. 2018. PMID: 29527635 Review.
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Wimmer K, Gampenrieder SP, Bartsch R, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Soelkner L, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162. N Engl J Med. 2021. PMID: 34320285 Clinical Trial.
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Gampenrieder SP, Pircher M, Fesl C, Rinnerthaler G, Mlineritsch B, Greil-Ressler S, Steger GG, Sagaster V, Fitzal F, Exner R, Devyatko Y, Balic M, Stöger H, Suppan C, Bauernhofer T, Singer CF, Pfeiler G, Seifert M, Helfgott R, Heck D, Rumpold H, Kwasny W, Wieder U, Gnant M, Greil R. Gampenrieder SP, et al. Among authors: devyatko y. Breast Care (Basel). 2022 Apr;17(2):137-145. doi: 10.1159/000516157. Epub 2021 May 21. Breast Care (Basel). 2022. PMID: 35707180 Free PMC article.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. Lancet. 2015. PMID: 26040499 Clinical Trial.